Mirati Therapeutics, Inc. financial data

Symbol
MRTX on Nasdaq
Industry
Pharmaceutical Preparations
Location
3545 Cray Court, San Diego, California
State of incorporation
Delaware
Fiscal year end
December 31

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 695 % -32.4%
Quick Ratio 6.35 %
Debt-to-equity 21.1 % +46.3%
Return On Equity -82.2 % -36%
Return On Assets -67.8 % -28.5%
Operating Margin -2K % +68.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 70.1M shares +21.8%
Common Stock, Shares, Outstanding 70.1M shares +21.8%
Entity Public Float 3.7B USD -50%
Common Stock, Value, Issued 70K USD +20.7%
Weighted Average Number of Shares Outstanding, Basic 65M shares +15.6%
Weighted Average Number of Shares Outstanding, Diluted 65M shares +15.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 38.2M USD +224%
Research and Development Expense 507M USD -6.86%
General and Administrative Expense 213M USD +79.4%
Operating Income (Loss) -765M USD -2.68%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -162M USD +6.58%
Income Tax Expense (Benefit) 0 USD -100%
Net Income (Loss) Attributable to Parent -726M USD +1.64%
Earnings Per Share, Basic -12.2 USD/shares +9.01%
Earnings Per Share, Diluted -12.2 USD/shares +9.01%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 259M USD -13.4%
Marketable Securities, Current 718M USD -20.4%
Accounts Receivable, after Allowance for Credit Loss, Current 14.7M USD
Inventory, Net 20.2M USD
Assets, Current 1.04B USD -15.5%
Property, Plant and Equipment, Net 16M USD -10.4%
Operating Lease, Right-of-Use Asset 35.1M USD -3.82%
Other Assets, Noncurrent 24.8M USD +17.9%
Assets 1.13B USD -13.3%
Employee-related Liabilities, Current 34.5M USD +20.8%
Accrued Liabilities, Current 99.4M USD -7.55%
Liabilities, Current 137M USD +8.18%
Operating Lease, Liability, Noncurrent 42.2M USD -4.29%
Other Liabilities, Noncurrent 3.66M USD +24.1%
Liabilities 183M USD +5.29%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1.55M USD +74.7%
Retained Earnings (Accumulated Deficit) -2.98B USD -32.3%
Stockholders' Equity Attributable to Parent 946M USD -16.2%
Liabilities and Equity 1.13B USD -13.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -190M USD -18.5%
Net Cash Provided by (Used in) Financing Activities 1.73M USD -31.7%
Net Cash Provided by (Used in) Investing Activities 195M USD +294%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 70.1M shares +21.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6.67M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 259M USD -13.4%
Deferred Tax Assets, Valuation Allowance 620M USD +47.2%
Deferred Tax Assets, Gross 628M USD +46.4%
Operating Lease, Liability 51.5M USD +12.2%
Depreciation 2.8M USD +55.6%
Payments to Acquire Property, Plant, and Equipment 269K USD -76.4%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -721M USD +4.3%
Property, Plant and Equipment, Gross 23M USD +23.5%
Operating Lease, Liability, Current 8.02M USD +11.9%
Deferred Tax Assets, Operating Loss Carryforwards 255M USD -14.8%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Additional Paid in Capital 3.92B USD +15.9%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 1M USD
Depreciation, Depletion and Amortization 1.08M USD +70.9%
Deferred Tax Assets, Net of Valuation Allowance 8.23M USD +4.04%
Share-based Payment Arrangement, Expense 193M USD +21.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%